Envision Healthcare Announces Closing of Second and Final Phase of Refinancing Transaction

NASHVILLE, Tenn.–(BUSINESS WIRE)–Envision Healthcare, a leading national medical group, today announced that it closed the second and final phase of the refinancing transaction that initially closed on July 22, 2022. All lenders under Envision Healthcare’s first lien term loan facility were provided the opportunity to participate in the transaction, with lenders holding approximately 96% of … [Read more…]

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on … [Read more…]

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited … [Read more…]

Synthetic Biology Market Global Outlook and Forecast 2022-2027: Significant Rise in Investments Fueling Sector Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Synthetic Biology Market – Global Outlook and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global synthetic biology market is expected to grow at a CAGR of 25% during 2022-2027. Synthetic biology is a new interdisciplinary field that includes the application of engineering principles to biology. It intends to design and … [Read more…]

Two Day Virtual Seminar: FDA Compliance and Clinical Trial Computer System Validation Core Requirements, Expectations and Challenges – August 23-24, 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “FDA Compliance and Clinical Trial Computer System Validation Core Requirements, Expectations and Challenges” training has been added to ResearchAndMarkets.com’s offering. In this two-day Virtual Seminar you will learn about FDA’s expectations for classifying, assessing the risk, testing, and validating a computer system used in clinical trial work. You will learn in detail about … [Read more…]

Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests … [Read more…]

Renowned Biopharma Leaders Join Newly Established Kallyope Clinical Development Advisory Board

NEW YORK–(BUSINESS WIRE)–Kallyope, Inc., a leading biotechnology company focused on identifying and developing therapeutics involving the gut-brain axis, today announced the formation of its inaugural Clinical Development Advisory Board. The board is composed of four distinguished physicians and scientists who will contribute insights from their vast experience as Kallyope advances its proprietary drug discovery platform, … [Read more…]

Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Announced analyses from Phase I study of etavopivat in sickle cell disease indicated reduction of reported pain-related adverse events, supporting potential to reduce vaso-occlusive crises Recently entered into an exclusive license agreement with Rigel Pharmaceuticals, Inc. for olutasidenib, a mutant IDH1 inhibitor for the potential treatment of relapsed or refractory acute myeloid leukemia Highlighted progress … [Read more…]

Click Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

NEW YORK–(BUSINESS WIRE)–Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced that Randall Stanicky, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 12:30 p.m. ET. Company management will also participate in one-on-one meetings during the conference, which will … [Read more…]